Title of cohort

    German National Cohort

    Acronym for cohort

    GNC

    Name of Principal Investigator - Title

    Prof

    Name of Principal Investigator - First name

    Karl-Heinz

    Name of Principal Investigator - Last name

    Joeckel

    Address of institution -Institution

    University Clinic Essen, Institute of Medical Informatics, Biometry, and Epidemiology

    Address of institution - Street address

    Hufelandstraße 55

    Address of institution - City

    Essen

    Address of institution - Postcode

    45122

    Country

    Germany

    Contact email
    Funding source

    Combined national and regional funding

    Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

    Alzheimer's disease and other dementias| Parkinson's disease| Neurodegenerative disease in general

    Q1b. When are studies on the above condition(s) expected to become possible?

    Q2a. In a single sentence what is the stated aim of the cohort?

    Its aim is to investigate the causes for the development of major chronic diseases, i.e. cardiovascular diseases, cancer, diabetes, neurodegenerative/-psychiatric diseases, musculoskeletal diseases, respiratory and infectious diseases, and their pre-clinical stages or functional health impairments.

    Q2b. What distinguishes this cohort from other population cohorts?

    This is a national initiative of enormous size. More than 200.000 people will be recruited for this study.

    Q3a. i) Number of publications that involve use of your cohort to date

    0

    Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)

    Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

    Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population

    urine, salvia, feces, nasal swabs

    Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

    20

    Q4a. Study criteria: what is the age range of participants at recruitment? To:

    70

    Q4b. Study criteria: what are the inclusion criteria?

    n/a

    Q4c. Study criteria: what are the exclusion criteria?

    n/a

    Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

    More than 15,000 participants

    Q6a. Please describe what measures are used to characterise participants

    n/a

    Q6b. Are there additional measures for participants with a clinical disorder?

    Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

    No

    If yes please specify

    Q7. What is the study design (select all that apply)?

    Prospective cohort| Longitudinal

    Q8. Are your cases matched by

    Age

    Q9a. Does your study include a specialised subset of control participants?

    No

    Q9b. If your study includes a specialised subset of control participants please describe

    Q10a. i) Please enter the data collection start date

    01/01/2013

    Q10a. ii) Please enter the data collection end date

    31/12/2023

    Q10a. iii) Is data collection for this study

    At the planning stage

    Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

    Yes - funding applied for/funding awarded

    Q11. Is data collected

    Only through the study

    Other please specify here

    Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

    Yes (participants given permission to be re-contacted via PIs)

    Q13a. Please give information on the format and availability of data stored in a database (1)

    % available

    Q13a. Please give information on the format and availability of data stored in a database (2)

    % available

    Q13a. Please give information on the format and availability of data stored in a database (3)

    % available

    Q13a. Please give information on the format and availability of data stored in a database (4)

    % available

    Other (please specify)

    % available

    Q13b. Please give information on the format and availability of data held as individual records (1)

    % available

    Q13b. Please give information on the format and availability of data held as individual records (2)

    % available

    Q13b. Please give information on the format and availability of data held as individual records (3)

    % available

    Q13b. Please give information on the format and availability of data held as individual records (4)

    % available

    Please specify language used

    Q14a. Is data available to other groups?

    Yes

    Q14b. If data is available to other groups what is the access policy/mechanisms for access?

    Q15. What data sharing policy is specified as a condition of use?

    Data made publicly available after a specified time point

    Q16a. Are tissues/samples/DNA available to other groups?

    Yes

    Q16b i) If yes, please describe below:

    Living donors: blood| Living donors: DNA

    Q16b. ii) In what form are tissues/samples/DNA supplied?

    Primary Samples: Stabilised samples (frozen or fixed)| Secondary samples: plasma| Secondary samples: DNA| Secondary samples: RNA| Secondary samples: protein extracts

    Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

    Yes

    Q17. Is information on biological characteristics available to other groups?

    Yes, for all the cohort

    Number of Patients

    % of total cohort

Types: Population Cohorts
Member States: Germany
Diseases: Alzheimer's disease & other dementias, Neurodegenerative disease in general, Parkinson's disease & PD-related disorders
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF